ALLK Allakos Inc.

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Latest News

1. 14 March 2019 Allakos Reports Fourth Quarter and Full Year 2018 Financial Results and 2018 Corporate Highlights
2. 11 March 2019 State-backed VC vehicle managers aren't worried about dipping into tax credits – here's why
3. 19 February 2019 Allakos Announces Positive Phase 1 Results with AK002 in Indolent Systemic Mastocytosis
4. 14 February 2019 Allakos Enters Oversold Territory
5. 11 February 2019 Allakos Announces Positive Phase 2 Results for AK002 in Patients with Xolair Refractory Chronic Spontaneous Urticaria and Provides Additional Data from Chronic Urticaria Study Cohorts
6. 04 February 2019 Allakos to Host Investor Day on February 19 in New York City
7. 29 January 2019 Allakos Announces Positive Phase 2 Results in Patients with Cholinergic Urticaria and Symptomatic Dermographism
8. 07 January 2019 Allakos Announces Positive Phase 2 Results in a Cohort of Xolair-Naïve Chronic Spontaneous Urticaria Patients
9. 02 January 2019 Here are the winners and losers from Bay Area's IPO class of 2018
10. 27 December 2018 5 Best-Performing IPOs of 2018
11. 21 December 2018 Allakos (ALLK) Catches Eye: Stock Jumps 6.5%
12. 26 November 2018 Here's how much better insiders have profited from this year's IPO boom
13. 22 November 2018 Has Allakos Inc (NASDAQ:ALLK) Got Enough Cash?
14. 21 November 2018 New Research Coverage Highlights TheStreet, EVO Payments, Odyssey Marine Exploration, Allakos, SORL Auto Parts, and SPAR Group — Consolidated Revenues, Company Growth, and Expectations for 2018
15. 08 November 2018 Allakos Announces Clinical Update and Third Quarter 2018 Financial Results
16. 13 August 2018 Mixed Reviews For Allakos As Sell-Side Starts Coverage Of Biotech